France · Delayed Price · Currency is EUR Exosens Earnings Call Transcripts
Fiscal Year 2026
-
Revenue grew 15.3% year-over-year to EUR 253.1 million, with strong gains in both Amplification and Detection & Imaging. Adjusted EBITDA margin reached a record 33%, and guidance for 2026 is now at the upper end of previous ranges, supported by robust demand and ongoing capacity expansion.
Fiscal Year 2025
-
Delivered record 2025 results with 22% revenue growth, 32.4% EBITDA margin, and strong cash flow. Upgraded 2026 guidance, continued capacity expansion, and strategic M&A support midterm ambition to reach EUR 1 billion revenue.
-
H1 2025 saw 20% revenue growth and 24% adjusted EBITDA growth, driven by strong defense demand, acquisitions, and margin expansion. Capacity investments and a robust backlog support positive guidance for 2025, with continued focus on R&D and selective M&A.
Fiscal Year 2024
-
Revenue grew 35% to EUR 394 million in 2024, with EBITDA margin at 30.1% and net profit up 66%. Strong defense demand, capacity expansion, and successful M&A drove results. 2025 guidance anticipates continued double-digit growth and further margin improvement.